Literature DB >> 1191576

Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs.

P M Mannucci, M Aberg, I M Nilsson, B Robertson.   

Abstract

Adrenaline, nicotinic acid (NA), vasopressin (LVP) and other drugs affecting vascular motility are known to increase plasminogen activator (PA) and factor-VIII plasma levels in man. To evaluate the hypothesis that NA, LVP and adrenaline release PA from the endothelial cells of the vessel wall through their common effect on vascular motility, PA has been characterized by means of a histochemical technique on vein biopsies obtained from human volunteers after infusion of the compounds. Furthermore, the effect of single and repeated administration has been compared in order to investigate whether the pattern of PA and factor-VIII variations in plasma is similar with the three drugs. There was no major difference in the PA content of the veins following the marked and sustained increase of the corresponding plasma activities. A simple explanation is that the intensity and duration of the stimulus may not be sufficient to deplete the large stores of the vessel walls. The magnitude, time course and duration of the plasmatic response after single and repeated infusions was on the whole different and peculiar for each drug. A derivative of LVP which is free of vasoactive actions was more effective than LVP in inducing the responses, which could also be elicited in two anephric subjects. These findings suggest that vasoactivity is unlikely to provide the clue to a common pathway for the fibrinolysis and coagulation response after the compounds, and support the existence of different specific receptors.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1191576     DOI: 10.1111/j.1365-2141.1975.tb00521.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  31 in total

1.  The effects of epinephrine infusion in patients with von Willebrand's disease.

Authors:  F R Rickles; L W Hoyer; M E Rick; D J Ahr
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

2.  Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I.

Authors:  S Lethagen; A S Harris; I M Nilsson
Journal:  Blut       Date:  1990-03

3.  Regulation of Hemostasis by the Sympathetic Nervous System: Any Contribution to Coronary Artery Disease?

Authors:  Daniel Preckel; Roland von Känel
Journal:  Heartdrug       Date:  2004

4.  Life threatening haemoptysis in cystic fibrosis: an alternative therapeutic approach.

Authors:  D Bilton; A K Webb; H Foster; P Mulvenna; M Dodd
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

5.  Factor VIII R:Ag as a prognostic parameter in intracranial haemorrhage.

Authors:  W S Almaani; A S Awidi; M Z Karmi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-02       Impact factor: 10.154

6.  The use of blood components in the treatment of congenital coagulation disorders.

Authors:  I M Nilsson; S A Larsson; S E Bergentz
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

7.  Use of desmopressin in the treatment of hemophilia A: towards a golden jubilee.

Authors:  Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2018-03       Impact factor: 9.941

Review 8.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

9.  The role of the 5'-flanking region in the cell-specific transcription of the human von Willebrand factor gene.

Authors:  V Ferreira; Z Assouline; J L Schwachtgen; B R Bahnak; D Meyer; D Kerbiriou-Nabias
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

10.  Antihaemophilic effect of vasopressin, deamino-(D-arginine8)-vasopressin and adrenaline in sheep: proposal for an in vivo assay system.

Authors:  J Heiniger; L Kissling-Albrecht; S Neuenschwander; R Rösli; V Pliska
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.